Industry
Biotechnology
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Loading...
Open
29.91
Mkt cap
4.5B
Volume
662K
High
31.26
P/E Ratio
-13.87
52-wk high
45.58
Low
29.67
Div yield
N/A
52-wk low
24.67
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 10:43 am
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 2:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 10:14 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 5:06 pm
Portfolio Pulse from Vandana Singh
September 09, 2024 | 4:54 pm
Portfolio Pulse from Avi Kapoor
September 09, 2024 | 1:12 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 7:59 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.